Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study

Phase 3positiveBria-IMTPositive

AI Analysis

Summary

BriaCell's independent Data Safety Monitoring Board issued its seventh consecutive positive recommendation to continue the Phase 3 Bria-ABC study evaluating Bria-IMT plus immune checkpoint inhibitor in metastatic breast cancer patients.

Clinical Trial Data

Phase

Phase 3

NCT ID

NCT06072612

Outcome Details

Independent Data Safety Monitoring Board issued seventh consecutive positive recommendation to continue the Phase 3 Bria-ABC study

Importance:7/10

Sentiment:

0.80

immunotherapycancerDSMB recommendationbreast cancercheckpoint inhibitor

Related Companies

$BCTX

Read the original article

Published by GlobeNewswire Clinical Studies on September 14, 2026 11:30 AM

Read Original